A Phase 3 interventional study of CM310 and placebo in Atopic Dermatitis, sponsored by Keymed Biosciences Co.Ltd. Completed at 1 site in China. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-10-02.
Sponsored by Keymed Biosciences Co.Ltd · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing stapokibart in Dermatitis, Atopic — 2 open to participants now, 3 under way, 3 of them phase 3. stapokibart · Dermatitis, Atopic.
Among the 12 studies testing stapokibart in Dermatitis, Atopic, this one is the 5th largest by enrollment, is one of 2 that started in 2024, is one of 5 in phase 3, and was the 9th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →2 of the 12 studies testing stapokibart in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:
Keymed Biosciences Co.Ltd · Sites in China
Ages 2–12
Keymed Biosciences Co.Ltd · Sites in China
Ages 2–11
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 12 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 5
First in 2020; this study’s year is marked. 2 started in 2024.
This study's enrollment of 180 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 170 across the 12 interventional studies. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 1 most frequent:
Keymed Biosciences Co.Ltd is the lead sponsor of 68 studies on the registry; 34 are open to participants now.
18 studies in Dermatitis, Atopic by Keymed Biosciences Co.Ltd: 4 open now, 5 under way, 3 of them phase 3. Of 10 finished, 0 (0%) have results posted.
Among the 18 studies in Dermatitis, Atopic by Keymed Biosciences Co.Ltd, this one is the 8th largest by enrollment, is one of 3 that started in 2024, is one of 5 in phase 3, and was the 12th registered.
Keymed Biosciences Co.Ltd’s Dermatitis, Atopic studies by the year they started, since 2020.
1 of the studies testing stapokibart in Dermatitis, Atopic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07106372Phase 3Keymed Biosciences Co.LtdA Study of Stapokibatrt in Children Subjects With Atopic Dermatitis | 2027-02 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing stapokibart in Dermatitis, Atopic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Keymed Biosciences Co.Ltd’s 18 in Dermatitis, Atopic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multi-center, randomized, double blind, placebo-controlled phase 3 study to evaluate the efficacy, safety, pharmacokinetics(PK), pharmacodynamics(PD) and immunogenicity of CM310 in children patients with moderate-to-severe atopic dermatitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: CM310
Other: placebo
Interleukin-4 receptor(IL-4Rα) monoclonal antibody
Placebo
Proportion of subjects achieving EASI-75 at week 18
The EASI is a composite index with scores ranging from 0 to 72. Four AD disease characteristics (erythema, edema/papulation, excoriation, lichenification) will each be assessed for severity by the investigator on a scale of "0" (none) through "3" (severe).
Time frame: Up to week 18
Proportion of subjects with IGA score of 0 or 1 and a reduction of IGA score by ≥2 points from baseline
Proportion of subjects with Investigator's Global Assessment (IGA) score of 0 or 1 and a reduction of IGA score by ≥2 points from baseline at week 18. IGA is an assessment instrument used in clinical studies to rate the severity of AD globally, based on a 5-point scale ranging from 0 (clear) to 4 (severe).
Time frame: up to week 18
Percent change of Eczema Area and Severity Index (EASI) score from baseline
The EASI is a composite index with scores ranging from 0 to 72. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) will each be assessed for severity by the investigator on a scale of "0" (absent) through "3" (severe).
Time frame: up to week 18
Percent change of NRS score from baseline
The range of Pruritus Numerical Rating Scale (NRS) is from 0 (no itch)-10 (worst imaginable itch)
Time frame: up to week 18
Body surface area (BSA) of involvement of atopic dermatitis
Change from baseline in percent of BSA
Time frame: up to week 18
Children Dermatology Life Quality Index (CDLQI)
Changes from baseline in CDLQI
Time frame: up to week 18
Patient-Oriented Eczema Measure (POEM)
Changes from baseline in POEM
Time frame: up to week 18
EuroQol Five Dimensions Questionnaire (EQ-5D)
Changes from baseline in EQ-5D
Time frame: up to week 18
Safety parameters
Incidence of Adverse Event(AE), abnormal physical examinations, abnormal vital signs, abnormal ECG, and abnormal lab testing.
Time frame: up to week 26
Pharmacokinetics parameters
Trough concentration and exposure of CM310
Time frame: up to week 26
Pharmacodynamics
Serum concentration of Thymus and activation regulated chemokine (TARC) , total immunoglobulin E (IgE) and lactate dehydrogenase (LDH)
Time frame: up to week 26
Immunogenicity
Detection of anti-drug antibody (ADA)
Time frame: up to week 26
Plan to share: No
Ran from Mar 2024 to primary completion in Jan 2025, 10 months.
Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 10 months is below that.
Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Stapokibart